25 Teclistamab (Tecvayli) Clinical Trials Recruiting Now (June 2026): BCMA × CD3 Bispecific, MajesTEC-4 + MajesTEC-7 Phase 3, Post-Anti-CD38 RRMM, AL Amyloidosis, SubQ Administration

Last updated: June 15, 2026

📌 Why this page exists: Teclistamab (Tecvayli) is the first-in-class BCMA-targeted T-cell engager approved for multiple myeloma — the leading BCMA bispecific class, and the off-the-shelf alternative to BCMA CAR-T (cilta-cel, ide-cel). Most recruiting trials are testing earlier-line combinations, post-transplant maintenance, MRD-driven consolidation, smoldering MM early intervention, and AL amyloidosis. For the full multiple myeloma trial landscape (other BCMA bispecifics, GPRC5D, cevostamab FcRH5, CAR-T, CELMoDs, smoldering), see our multiple myeloma trials page. For the sibling GPRC5D bispecific from the same Janssen program, see our talquetamab (Talvey) page.

About Teclistamab (Tecvayli)

Drug profile:

Teclistamab (brand name Tecvayli, code JNJ-64007957, USAN teclistamab-cqyv) is a first-in-class BCMA × CD3 bispecific T-cell engager developed by Janssen Biotech / Johnson & Johnson. One arm binds BCMA (B-cell maturation antigen — a TNF-receptor superfamily member highly expressed on plasma-cell-lineage tumor cells) and the other arm binds CD3 on T cells, redirecting the patient's own T cells to attack BCMA-expressing myeloma cells. Teclistamab is administered as a subcutaneous injection with step-up dosing in cycle 1.

Why BCMA matters as a target:

BCMA is the most-validated multiple myeloma target after CD38. Three BCMA bispecific T-cell engagers are now FDA-approved (teclistamab, elranatamab / Elrexfio, linvoseltamab / Lynozyfic), alongside two BCMA CAR-T products (idecabtagene vicleucel / ide-cel / Abecma; ciltacabtagene autoleucel / cilta-cel / Carvykti) and the BCMA-directed ADC belantamab mafodotin. Teclistamab was first in class, achieved BCMA × CD3 bispecific approval on the strength of MajesTEC-1, and remains the reference benchmark — the head-to-head Phase 3 NCT07518186 against the BCMA × GPRC5D dual-bispecific JNJ-79635322 is structured around teclistamab as the active comparator.

Regulatory status:

FDA accelerated approval, October 25, 2022 — for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Approval was based on the Phase 1/2 MajesTEC-1 study. Accelerated approval requires confirmatory Phase 3 data; the Phase 3 confirmatory program (including MajesTEC-4 maintenance, MajesTEC-7 in newly diagnosed transplant-ineligible MM, the Tal-Tec arm of NCT06208150 in earlier-line RRMM, and JNJ-79635322 head-to-head vs teclistamab) is ongoing. We do not claim full (traditional) approval on this page — readers should check the current FDA prescribing information for the most up-to-date status.
Outside the US: conditional marketing authorization in the EU (August 2022) and approvals in several other jurisdictions on the same MajesTEC-1 dataset.

Active Research Directions in 2026

Phase 3 in transplant-ineligible newly diagnosed MM (MajesTEC-7) — NCT05552222 compares Tec-DR (teclistamab + daratumumab + lenalidomide) and Tal-DR (talquetamab + daratumumab + lenalidomide) head-to-head against DRd (daratumumab + lenalidomide + dexamethasone) in newly diagnosed transplant-ineligible MM or patients not intended for ASCT as initial therapy. The cleanest direct comparison of a BCMA bispecific induction vs a GPRC5D bispecific induction in the same trial — and the registrational study that could move teclistamab into front-line transplant-ineligible MM.
Phase 3 post-transplant maintenance (MajesTEC-4) — NCT05243797 compares teclistamab + lenalidomide and teclistamab alone vs lenalidomide alone as maintenance therapy after autologous stem cell transplant in newly diagnosed MM. If positive, this trial moves teclistamab into the maintenance setting and competes directly with lenalidomide as the post-transplant standard of care.
Phase 3 in earlier-line RRMM (post anti-CD38 + lenalidomide) — NCT06208150 (sponsor protocol 64407564MMY3009) includes a teclistamab arm in combination with talquetamab (Tal-Tec) tested vs talquetamab + pomalidomide (Tal-P) and vs investigator's choice EPd or PVd. Even though the primary intent of NCT06208150 is moving talquetamab into earlier lines, the Tal-Tec arm is the most consequential read-out for teclistamab in 1–3 prior line settings.
Phase 3 head-to-head vs the next-generation dual-bispecific JNJ-79635322 — NCT07518186 is the first Phase 3 randomized study comparing JNJ-79635322 (a BCMA × GPRC5D dual-target T-cell engager from the same Janssen program) against teclistamab as the active comparator, in RRMM after 1–3 prior lines (including anti-CD38 + lenalidomide). The trial will answer whether dual-target engagement improves over single-BCMA engagement — with teclistamab established as the relevant benchmark.
Smoldering myeloma (early intervention) — REVIVE — NCT06100237 tests teclistamab + daratumumab (subcutaneous) in high-risk smoldering myeloma in a Phase 2 immuno-oncology study. Part of the broader 2026 trend of moving T-cell engagers before active MM, in patients who would otherwise wait for organ damage before treatment.
MRD-driven response-adaptive consolidation — ROTATE (NCT06993675) and NCT06505369 use sequential teclistamab + talquetamab consolidation in newly diagnosed MM to eliminate minimal residual disease. NCT06758375 uses low-dose teclistamab as consolidation in first-line NDMM.
Earlier-line combinations with CELMoDs — NCT06465316 (teclistamab + iberdomide, Phase 1b) and NCT07105059 (teclistamab + mezigdomide, Phase 1) test teclistamab with the next-generation cereblon modulators in RRMM, including in BCMA-naive and BCMA-exposed populations.
Alternating-induction novel design (ALTITUDE) — NCT07099391 alternates Dara-RVd and Teclistamab-RVd cycles in transplant-eligible standard-risk newly diagnosed MM — the first registrational-style test of whether bispecific-anchored induction can be alternated with established quadruplet induction to deepen response.
Outpatient administration of step-up dosing — NCT05972135 (outpatient administration of teclistamab or talquetamab) and NCT06251076 (outpatient step-up plan development in academic and community centers, including caregiver burden) test whether the FDA-required hospitalization for cycle-1 step-up doses — the main operational bottleneck for adoption — can be safely eliminated.
AL amyloidosis — six dedicated Phase 2 trials test teclistamab in light-chain amyloidosis (a plasma-cell-driven disease that also expresses BCMA): previously treated AL (NCT06649695, NCT06699394, NCT06935162), newly diagnosed high-risk Mayo Stage IIIB AL (NCT07079423), teclistamab + daratumumab in AL (NCT07110844), and concurrent MM + AL (NCT07638683). AL amyloidosis is a critical extension because patients are often too frail for transplant and have organ failure that limits chemotherapy options.

Recruiting Trials by Setting

Phase 3 — Multiple Myeloma (4 trials)

The four Phase 3 trials below are the registrational program that will move teclistamab into earlier lines, maintenance, and define its role against the next-generation dual-bispecific:

NCT05552222 — MajesTEC-7 (Phase 3; Recruiting): Teclistamab + daratumumab + lenalidomide (Tec-DR) and talquetamab + daratumumab + lenalidomide (Tal-DR) vs daratumumab + lenalidomide + dexamethasone (DRd) in newly diagnosed transplant-ineligible MM or patients not intended for ASCT. Direct comparison of BCMA bispecific induction vs GPRC5D bispecific induction in the same trial.
NCT05243797 — MajesTEC-4 (Phase 3; Recruiting): Teclistamab + lenalidomide and teclistamab alone vs lenalidomide alone as maintenance therapy following autologous stem cell transplantation in newly diagnosed MM. The registrational study for teclistamab in the post-ASCT maintenance setting.
NCT06208150 — 64407564MMY3009 (Phase 3; Recruiting): Includes a Tal-Tec arm (talquetamab + teclistamab) alongside Tal-P (talquetamab + pomalidomide) vs investigator's choice EPd (elotuzumab + pomalidomide + dexamethasone) or PVd (pomalidomide + bortezomib + dexamethasone) in RRMM after anti-CD38 + lenalidomide. The earlier-line registrational read-out for teclistamab in the bispecific-doublet setting.
NCT07518186 — JNJ-79635322 vs Teclistamab (Phase 3; Recruiting): Head-to-head Phase 3 comparing JNJ-79635322 (BCMA × GPRC5D dual-target T-cell engager) vs teclistamab in RRMM after 1–3 prior lines (including anti-CD38 + lenalidomide). First Phase 3 to use teclistamab as an active comparator rather than the experimental arm — an important inflection point for the field.

Newly Diagnosed and Transplant Setting (Phase 1–2) (5 trials)

NCT05695508 — MajesTEC-5 / GMMG-HD10 / DSMM-XX (Phase 2; Recruiting): Teclistamab-, talquetamab-, and JNJ-79635322-based combination regimens as induction and post-transplant maintenance in newly diagnosed transplant-eligible MM.
NCT05572229 — Tec + Dara / Tec + Len in Elderly NDMM (Phase 2; Recruiting): Teclistamab in combination with daratumumab or lenalidomide in elderly patients with newly diagnosed MM.
NCT06758375 — Low-Dose Tec Consolidation in NDMM (Phase 2; Recruiting): Low-dose teclistamab as consolidation in first-line treatment of newly diagnosed MM — tests whether attenuated dosing preserves efficacy while reducing CRS and infection events.
NCT07099391 — ALTITUDE (Phase 1/2; Recruiting): Alternating Dara-RVd / Teclistamab-RVd in transplant-eligible standard-risk newly diagnosed MM — first trial to alternate quadruplet induction with bispecific-anchored induction.
NCT07107529 — EMN 37 FITFIX FOR FRAIL (Phase 2; Recruiting): Daratumumab + teclistamab (Tec-D) or daratumumab + talquetamab (Tal-D) as fixed-duration treatment for frail patients with newly diagnosed MM. Two parallel cohorts.

High-Risk Smoldering Myeloma (Early Intervention) (1 trial)

NCT06100237 — REVIVE (Phase 2; Recruiting): Teclistamab in combination with daratumumab SC for high-risk smoldering myeloma. Clinical and correlative immuno-oncology study — tests whether early intervention with a BCMA bispecific can delay or prevent the transition to active MM.

MRD-Driven Consolidation (Phase 2) (2 trials)

NCT06505369 — Bispecific T-cell Redirector Consolidation (Phase 2; Recruiting): Teclistamab and talquetamab in sequence as consolidation in transplant-eligible newly diagnosed MM, with the goal of improving MRD-negative complete response rates.
NCT06993675 — ROTATE (Phase 2; Recruiting): Response-adaptive consolidation in newly diagnosed MM — participants who remain MRD-positive after front-line induction + transplant receive consolidation with teclistamab and/or talquetamab to convert to MRD-negative.

Late-Line / Triple-Class Refractory RRMM (3 trials)

The currently-approved setting (4+ prior lines including anti-CD38 + PI + IMiD) and adjacent triple-class refractory combinations:

NCT05932680 — Limited-Duration Teclistamab (Phase 2; Recruiting): Single-arm, non-inferiority study of fixed-duration teclistamab for RRMM, addressing whether stopping treatment after a defined period reduces cumulative infection / hypogammaglobulinemia risk without sacrificing depth or duration of response.
NCT06465316 — Teclistamab + Iberdomide (Phase 1b; Recruiting): Teclistamab (Tecvayli) plus the CELMoD iberdomide in RRMM — tests whether next-generation cereblon modulators amplify BCMA bispecific activity in heavily pretreated populations.
NCT07105059 — Teclistamab + Mezigdomide (Phase 1; Recruiting): Teclistamab + mezigdomide in RRMM — the second CELMoD partner being formally tested with teclistamab.

Resistance and Sensitivity Mechanism (1 trial)

NCT05945524 — Single-Cell Immune Analysis of Teclistamab Resistance (Recruiting): Observational / correlative analysis of resistance and sensitivity mechanisms to teclistamab using single-cell immune profiling. Designed to identify why some patients respond durably while others lose response — foundational for the next generation of BCMA bispecifics and combinations.

Administration Optimization and Real-World Safety (3 trials)

The FDA label currently requires hospitalization for cycle-1 step-up doses — the main operational bottleneck for adoption in community oncology. Three active trials are working on moving teclistamab out of the inpatient setting:

NCT05972135 — Outpatient Administration of Teclistamab or Talquetamab (Phase 2; Recruiting): Tests whether step-up dosing and subsequent administration can be done safely in the outpatient setting, which would eliminate the hospitalization requirement.
NCT06251076 — Outpatient Step-Up Plan Development (Phase 4; Recruiting): Process-development study across academic and community centers for outpatient teclistamab step-up dosing in RRMM, with structured measurement of caregiver burden.
NCT07030517 — Teclistamab Safety in Indian Patients (Phase 4; Recruiting): Real-world evidence / post-marketing safety study of teclistamab in Indian patients with RRMM. Extends safety dataset into a population under-represented in the pivotal MajesTEC-1 trial.

AL (Light-Chain) Amyloidosis (6 trials)

AL amyloidosis is a plasma-cell-driven disease that also expresses BCMA. Because patients are frequently too frail for autologous transplant and have organ damage that limits chemotherapy options, BCMA bispecifics are a major area of investigation — teclistamab is the most-advanced BCMA bispecific being tested:

NCT06649695 — Teclistamab in Previously Treated AL Amyloidosis (Phase 2; Recruiting): Single-agent teclistamab in patients with previously treated immunoglobulin light-chain (AL) amyloidosis.
NCT06699394 — Prospective Teclistamab in Systemic AL Amyloidosis (Recruiting): Prospective study of teclistamab in the treatment of systemic AL amyloidosis.
NCT06935162 — Teclistamab in Previously Treated AL Amyloidosis (Phase 2; Recruiting): A second Phase 2 single-agent teclistamab study in previously treated AL amyloidosis.
NCT07079423 — Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis (Phase 2; Recruiting): Targets the highest-risk AL amyloidosis subgroup — patients with advanced cardiac involvement who have the shortest median survival on standard therapy.
NCT07110844 — Teclistamab + Daratumumab in AL Amyloidosis (Phase 2; Recruiting): Combination of teclistamab + daratumumab in AL amyloidosis — adds anti-CD38 to BCMA bispecific in the same population.
NCT07638683 — Tec-Dara in NDMM with Concurrent AL Amyloidosis (Phase 2; Recruiting): Teclistamab + daratumumab in newly diagnosed MM with concurrent light-chain amyloidosis (MM + AL) — addresses the practically important overlap population that is excluded from many MM-only trials.

Showing all 25 recruiting interventional trials of teclistamab in the ClinTrialFinder corpus as of June 15, 2026. View the latest teclistamab search on ClinicalTrials.gov.

Trials Not Yet Recruiting

NCT06880601 — TALIM (Phase 2; Not Yet Recruiting): Teclistamab plus autologous lymphocyte infusion (ALI) for relapsed/refractory MM — tests whether infusing the patient's own collected lymphocytes alongside teclistamab amplifies the effector-T-cell pool available for BCMA engagement.
NCT06948084 — DT vs DPd or DKd (Randomized Phase 2; Not Yet Recruiting): Daratumumab + teclistamab (DT) vs daratumumab + pomalidomide + dexamethasone (DPd) or daratumumab + carfilzomib + dexamethasone (DKd) in high-risk MM that is refractory or in first relapse. Pits the bispecific doublet directly against established triplets in early relapse / high-risk disease.
NCT07463807 — TP vs KPd Fixed-Duration in Early Relapse (Phase 1/2; Not Yet Recruiting): Fixed-duration teclistamab + pomalidomide (TP) vs carfilzomib + pomalidomide + dexamethasone (KPd) in MM that has relapsed shortly after prior treatment. Fixed-duration design directly addresses the cumulative infection risk of indefinite BCMA bispecific dosing.
NCT07605416 — QUANTUM (Phase 2; Not Yet Recruiting): Quadruplet induction followed by teclistamab consolidation and doublet maintenance in primary plasma cell leukemia — a rare, aggressive variant of plasma-cell disease with poor outcomes on conventional MM regimens.
NCT07332507 — Teclistamab in Plasmablastic Lymphoma (Phase 1b; Not Yet Recruiting): Teclistamab in relapsed/refractory plasmablastic lymphoma — an aggressive B-cell lymphoma with plasma-cell-like differentiation that frequently expresses BCMA.
NCT07631208 — Teclistamab in Anti-MDA5 ILD (Phase 2; Not Yet Recruiting): Teclistamab in severe rapidly progressive interstitial lung disease associated with anti-MDA5 autoantibodies — a non-oncology autoimmune indication. Tests whether depleting BCMA-expressing autoantibody-producing plasma cells can reverse a life-threatening autoimmune syndrome. We list it for transparency; it is outside the scope of this oncology page.

Patient Selection and Practical Considerations

BCMA expression is not measured before treatment — unlike some biomarker-driven therapies, FDA-approved use of teclistamab does not require pre-treatment confirmation of BCMA expression. Expression is presumed in myeloma plasma cells.
Hospitalization is required for the step-up doses — per the current FDA label, the cycle-1 step-up doses are administered with inpatient monitoring for cytokine release syndrome (CRS). Outpatient administration is being tested in NCT05972135 and NCT06251076.
Step-up dosing schedule — the cycle-1 schedule involves two priming (step-up) doses several days apart, followed by the full treatment dose, then ongoing weekly or every-other-week treatment depending on response.
Prior BCMA-directed therapy is generally a disqualifier for most teclistamab trials — if a patient has already progressed on a BCMA bispecific or BCMA CAR-T, the next-line options are typically a non-BCMA bispecific (talquetamab, etentamig, cevostamab) or CELMoD-anchored combination. See our talquetamab page for the GPRC5D sequencing trials.
Infection risk and IVIG support — teclistamab causes profound hypogammaglobulinemia (because BCMA is expressed on normal plasma cells too), and the risk of severe and opportunistic infection is the defining safety signal. Most patients receive antimicrobial prophylaxis (anti-PJP, anti-viral) and IVIG (intravenous immunoglobulin) replacement as part of supportive care, particularly during the first months of treatment and during infection events.
Fixed-duration / limited-duration teclistamab — standard label dosing is continuous, but several trials (NCT05932680, NCT07463807) explicitly test fixed-duration regimens to reduce cumulative infection and immune-suppression risk.
AL amyloidosis is a major non-MM use case — six dedicated Phase 2 trials are testing teclistamab in light-chain amyloidosis, including the newly diagnosed Mayo Stage IIIB high-risk subgroup. Patients with AL amyloidosis (with or without concurrent MM) should ask about these specifically.

Side Effects (Teclistamab-Specific Signals)

Teclistamab shares the broader CD3-engaging bispecific class profile (CRS, ICANS, cytopenias) but carries a teclistamab-specific signal that distinguishes BCMA bispecifics from the GPRC5D class (talquetamab, etentamig):

Severe infections and hypogammaglobulinemia — the defining BCMA-bispecific signal. BCMA is expressed on normal plasma cells as well as tumor cells, so engaging T cells against BCMA depletes the patient's antibody-producing plasma cells, leading to profoundly low IgG levels (hypogammaglobulinemia). Severe and opportunistic infections (including pneumocystis, CMV reactivation, viral upper respiratory infections, COVID-19, bacterial pneumonia) are the most common cause of treatment interruption and hospitalization. Prophylactic antimicrobials and IVIG (intravenous immunoglobulin) replacement are typically part of supportive care throughout treatment. This is the patient-noticeable signal that makes teclistamab biology and supportive care different from talquetamab (which depletes plasma cells via a different target and has its own dysgeusia / skin / nail signal but generally less severe infection burden).
Cytokine release syndrome (CRS) — mostly Grade 1–2, concentrated in cycle-1 step-up doses, generally manageable with tocilizumab, supportive care, and dose modification. Shared with all CD3-engaging bispecifics. The hospitalization requirement for cycle-1 step-up doses is specifically to monitor for CRS.
Immune effector cell-associated neurotoxicity syndrome (ICANS) — less frequent than with BCMA CAR-T, generally reversible. Includes confusion, headache, motor weakness, and rarely seizures.
Cytopenias — neutropenia, anemia, thrombocytopenia. Usually manageable with supportive care, growth factor support, and dose modification.
Injection site reactions — subcutaneous administration carries local redness, swelling, or pain at the injection site. Generally mild.

For the infection signal in particular, it is worth asking your care team in advance about IVIG replacement schedule, prophylactic antimicrobials, vaccinations (where appropriate), and what to do for fever or respiratory symptoms — the events that drive hospitalizations and treatment interruptions in practice.

Frequently Asked Questions

What is teclistamab (Tecvayli)?

Teclistamab (brand name Tecvayli, development code JNJ-64007957, USAN teclistamab-cqyv) is a first-in-class BCMA × CD3 bispecific T-cell engager developed by Janssen Biotech / Johnson & Johnson. One arm binds BCMA (B-cell maturation antigen) — a target highly expressed on plasma-cell-lineage tumor cells — and the other binds CD3 on T cells, redirecting the patient's own T cells against BCMA-expressing myeloma cells. It received FDA accelerated approval on October 25, 2022 for adults with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The approval was based on the Phase 1/2 MajesTEC-1 study. Teclistamab is given subcutaneously with step-up dosing in cycle 1.

What cancers is teclistamab being tested in?

Teclistamab is developed primarily for multiple myeloma and other plasma-cell disorders. The 25 recruiting trials in our corpus span newly diagnosed transplant-eligible and -ineligible MM, high-risk smoldering myeloma (REVIVE), relapsed/refractory MM after one or more prior lines, MRD-driven post-transplant consolidation and maintenance, outpatient administration, and AL (light-chain) amyloidosis (six dedicated Phase 2 trials including the newly diagnosed Mayo Stage IIIB high-risk subgroup and concurrent MM + AL). Not-yet-recruiting trials extend teclistamab into plasmablastic lymphoma, primary plasma cell leukemia (QUANTUM), and severe anti-MDA5 interstitial lung disease.

What teclistamab trials are currently recruiting?

There are 25 recruiting interventional teclistamab trials as of June 2026. The four Phase 3 trials are NCT05552222 (MajesTEC-7 — Tec-DR / Tal-DR vs DRd in newly diagnosed transplant-ineligible MM), NCT05243797 (MajesTEC-4 — teclistamab maintenance after autologous transplant), NCT06208150 (Tal-Tec arm in earlier-line RRMM post anti-CD38 + lenalidomide), and NCT07518186 (JNJ-79635322 BCMA × GPRC5D head-to-head vs teclistamab in 1–3 prior line RRMM). Newly diagnosed and transplant setting: MajesTEC-5 (NCT05695508), Tec + dara/len in elderly NDMM (NCT05572229), low-dose Tec consolidation (NCT06758375), ALTITUDE alternating Dara-RVd/Tec-RVd (NCT07099391), FITFIX FOR FRAIL (NCT07107529), Tec+Tal first-line consolidation (NCT06505369), ROTATE MRD-positive consolidation (NCT06993675), REVIVE high-risk smoldering MM (NCT06100237). Late-line / RRMM: limited-duration Tec (NCT05932680), Tec + iberdomide (NCT06465316), Tec + mezigdomide (NCT07105059), single-cell resistance mechanism study (NCT05945524). Administration: outpatient (NCT05972135), outpatient step-up plan (NCT06251076), Indian RWE safety (NCT07030517). AL amyloidosis: six trials (NCT06649695, NCT06699394, NCT06935162, NCT07079423, NCT07110844, NCT07638683).

What are the main side effects of teclistamab?

Teclistamab carries the side-effect profile of CD3-engaging bispecifics plus a teclistamab-specific signal: severe infections driven by hypogammaglobulinemia, because BCMA is expressed on normal plasma cells as well as tumor cells, so engaging T cells against BCMA depletes the antibody-producing plasma cells. Patients typically need prophylactic antimicrobials and IVIG (intravenous immunoglobulin) replacement throughout treatment. This is the patient-noticeable signal that distinguishes BCMA bispecifics from talquetamab (which has dysgeusia / skin / nail changes instead). Other side effects include cytokine release syndrome (CRS) — mostly Grade 1–2, concentrated in cycle-1 step-up doses, managed with tocilizumab — immune effector cell-associated neurotoxicity syndrome (ICANS) (less frequent than with CAR-T, generally reversible), cytopenias (neutropenia, anemia, thrombocytopenia), and injection site reactions. The FDA label requires hospitalization for the step-up doses; outpatient administration is being studied in NCT05972135 and NCT06251076.

Find Teclistamab and BCMA-Targeted Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find teclistamab and other BCMA-targeted multiple myeloma trials based on your prior treatments (anti-CD38, IMiD, PI, prior BCMA exposure), transplant status, and disease stage.

Find Matching Trials

This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or hematologist. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here.